scholarly journals Effect of Inhaled Magnesium Sulphate on Bronchodilating Response, Levels of Substance P and Clinical Improvement of Acute Exacerbations COPD Patients

2018 ◽  
Vol 38 (1) ◽  
pp. 16-23
Author(s):  
Prima Karita Sari ◽  
Suradi Suradi ◽  
Jatu Aphridasari
Keyword(s):  
Treatment Group ◽  
Substance P ◽  
Emergency Room ◽  
Acute Exacerbation ◽  
Magnesium Sulphate ◽  
Control Group ◽  
Acute Exacerbation Of Copd ◽  
Copd Patients ◽  
Significant Difference ◽  
Exacerbation Of Copd

Background: Inhaled magnesium sulphate has a bronchodilator and antiinflammatory effect by block the calcium channels and inhibiting substance P. This study aimed to analyze the effect of magnesium sulfate inhalation on bronchodilator response, substance P levels, and clinical improvement on AECOPD patients. Methods: A quasi-experimental clinical trial, pre-test and post-test design with 34 acute exacerbation of COPD patients who are hospitalized in emergency room on Dr. Moewardi Hospital, Surakarta and Ario Wirawan Hospital, Salatiga on March-April 2017 used consecutive sampling. The independent variable is inhaled magnesium sulphate dose of 150 mg 3 times every 20 minutes when the patients was admitted in emergency room, while the dependent variables are peak expiratory flow rate, the plasma levels of substance P and CAT score acute exacerbation of COPD patients. Results: There was a significant difference (P=0.009) decrease of PEFR value of treatment group (111.76±12.37) compared to control group (141.18±24.21). There was a significant difference (P=0.0001) decrease in CAT score of treatment group (-14.88±1.75) compared to control group (-9.00±1.17). There was a significant difference (P=0.0001) treatment group (-1305.92±417.91) than control group (-355.95±206.25). Conclucions: The addition of MgSO4 inhalation of 150 mg during exacerbation increased PEFR, decreased the level of P substance, and decreased the CAT score with statistically significant results. (J Respir Indo 2018; 38(1): 16-23)

scholarly journals Effects of Mangosteen pericarp Extract to Clinical Improvements, The Plasma Level of IL-6 and Malondialdehyde in Acute Exacerbation of COPD Patients

2018 ◽  
Vol 38 (3) ◽  
pp. 164-172
Author(s):  
Khilyatul Baroroh ◽  
Suradi Suradi ◽  
Ade Rima
Keyword(s):  
Treatment Group ◽  
Plasma Level ◽  
Length Of Stay ◽  
Acute Exacerbation ◽  
Clinical Symptoms ◽  
Control Group ◽  
Chronic Obstructive ◽  
Copd Patients ◽  
Significant Difference ◽  
And Control

Background: Amplification of inflammation in acute exacerbation of chronic obstructive pulmonary disease (COPD) increases inflammatory mediators and oxidative stress in the airways, pulmonary and systemic circulation that are characterized by increased plasma level of IL-6 and MDA, resulting in worsening of clinical symptoms. Xanthones in mangosteen pericarp have anti-inflammatory and antioxidant effects, potentially as an adjuntive therapy in acute exacerbations of COPD. Methods: The aim of this study was to determine the effect of mangosteen pericarp extract to clinical improvements, plasma level of IL-6 and MDA of acute exacerbation COPD patients. A clinical trial of experimental with pretest and posttest was conducted on 34 acute exacerbation of COPD patients in Dr. Moewardi Hospital Surakarta and Dr. Ario Wirawan Lung Hospital Salatiga from April until May 2016. The sample was taken by consecutive sampling. Subjects were divided by randomized double blind technique into the treatment group (n=17) received mangosteen pericarp extract 2x1100mg/day and control group (n = 17) received placebo. Clinical improvements were measured in CAT score and length of stay. CAT score, plasma level of IL-6 and MDA were measured on admission and at discharge. Length of stay based on the number of days of care in hospitals. Results: There was significant difference (p=0,011) towards decreased of IL-6 plasma level between treatment group (-2,17 ± 3,46 pg/ mL) and control group (+1,67 ± 6,81 pg/mL). There were no significant difference towards decreased of length of stay (p=0,34) between treatment group (4,12 ± 1,54 days) and control group (5,24 ± 2,49 days), towards decreased of CAT score (p=0,252) between treatment group (-19,18 ± 3,96) and control group (-18,24 ± 2,75), and towards decreased of MDA plasma level (p=0,986) between treatment group (+0,03 ± 0,36μmol/L) and control group (+0,35 ± 1,58). Conclusions: The addition of mangosteen pericarp extract 2x1100mg/day during hospitalization was significantly lowered plasma levels of IL-6, but were not significant in lowering the CAT score, shortening the length of stay, and reducing the increase in plasma level of MDA.

“RESPIRATORY VIRAL INFECTION: AN UNDERRATED ENTITY THAT NEED TO CONSIDER IN MANAGEMENT OF ACUTE EXACERBATION OF COPD”

2021 ◽  
pp. 6-8
Author(s):  
Gyan Singh Meena ◽  
Ajith Kumar M S ◽  
Shashank Sharma ◽  
SP Agnihotri
Keyword(s):  
Acute Exacerbation ◽  
Viral Infections ◽  
Respiratory Viruses ◽  
Cross Sectional Study ◽  
Viral Etiology ◽  
Cross Sectional ◽  
Acute Exacerbation Of Copd ◽  
Medical College ◽  
Copd Patients ◽  
Exacerbation Of Copd

BACKGROUND: Acute exacerbation of COPD (AECOPD) is one of the most common cause of hospital admission. It causes signicant morbidity, mortality and inexorable decline in ling function. Many exacerbations are believed to be due to upper and/ lower respiratory tract viral infections, but the incidence of these infections in patients with COPD is still undetermined. Objectives of the study are-(a) To nd out the viral etiology in patients having acute exacerbation of COPD. (b) To correlate the severity of COPD patients having exacerbations with viral etiology. METHODS: This cross-sectional study was carried out on 70 AECOPD patients admitted in department of Respiratory Medicine, Institute of Respiratory Diseases, SMS Medical College, Jaipur during July 2019–June 2020. Demographic and clinical parameters were recorded from each patient during admission. Twin nasopharyngeal/oropharyngeal swabs were collected and are tested for Respiratory viruses via RT-PCR. RESULTS: Respiratory viruses were detected in 15 of 70 (21.42%) patients during exacerbations of COPD. The viruses detected were inuenza (10%), rhinovirus (5.71%), adenovirus (4.29%) and RSV (1.42%). Majority of the patients had exacerbations in severe COPD subgroup, had duration of hospital stay of more than or equal to 5 days, had one episode of acute exacerbation per year and 5, 9, 11 respiratory viruses were detected in this group respectively. CONCLUSION: Viral infections seem to contribute to the exacerbations of COPD in our settings and should be strongly considered in the management of such patients. Considering appropriate antiviral therapy can timely reduce morbidity in an event of an inuenza viral exacerbation.

Effect of the Air Pollution on Acute Exacerbation of COPD Patients in Shanghai

CHEST Journal ◽  
2016 ◽  
Vol 149 (4) ◽  
pp. A343
Author(s):  
Xian Wen Sun ◽  
Qing Yun Li ◽  
Pei Li Chen ◽  
Lei Ni ◽  
Lei Ren ◽  
...  
Keyword(s):  
Air Pollution ◽  
Acute Exacerbation ◽  
Acute Exacerbation Of Copd ◽  
Copd Patients ◽  
Exacerbation Of Copd

scholarly journals PENGARUH PEMBERIAN INHALASI KOMBINASI SALMETEROL/FLUTIKASON PROPIONAT TERHADAP KUALITAS HIDUP PENDERITA PENYAKIT PARU OBSTRUKTIF KNONIK STABIL

2019 ◽  
Vol 1 (2) ◽  
pp. 28-33
Author(s):  
Refi Sulistiasari
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Treatment Group ◽  
Control Group ◽  
Copd Assessment Test ◽  
Copd Patients ◽  
Significant Difference ◽  
Inhaled Therapy ◽  
St George's Respiratory Questionnaire

It is known that inflammation is the underlying cause of COPD, and this affects to quality of life of the patient. Provision of inhaled therapy combination of LABA and corticosteroids is one of therapy in pharmacology of stable PPOK patients. The aim of this study was to know the benefits of inhalation of 50 g / fluticasone propionate 500 g inhibition in stable COPD patients. The research design is clinical trial. The study was conducted for 3 months and was performed on 26 stable COPD patients divided into two groups: 15 patients for the treatment group and 15 patients for the control group. After the measurements were obtained, there was a significant difference in the quality of life as measured by St. George's Respiratory Questionnaire (SGRQ) (p = 0.001) and COPD Assessment Test (CAT) (0.001) measurements were made twice on the first and thirtieth days.

Sign in / Sign up

Export Citation Format

Share Document